TG Therapeutics (TGTX) shares tumbled 5.71% in pre-market trading on Monday, August 4, 2025, despite the company reporting positive second-quarter financial results and raising its revenue guidance for its drug Briumvi.
The biotechnology company announced its Q2 2025 financial results early Monday, reporting product revenue of $138.843 million and a net income of $28.187 million. Additionally, TG Therapeutics raised its revenue guidance for Briumvi, its flagship multiple sclerosis treatment.
Despite these seemingly positive developments, investors appear to be reacting negatively, possibly indicating that the results or the raised guidance fell short of market expectations. The pre-market plunge suggests that Wall Street may have been anticipating even stronger performance or more optimistic forecasts from the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。